Arcutis Biotherapeutics Inc
NASDAQ:ARQT

Watchlist Manager
Arcutis Biotherapeutics Inc Logo
Arcutis Biotherapeutics Inc
NASDAQ:ARQT
Watchlist
Price: 29.47 USD -1.01% Market Closed
Market Cap: 3.6B USD

Wall Street
Price Targets

ARQT Price Targets Summary
Arcutis Biotherapeutics Inc

Wall Street analysts forecast ARQT stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ARQT is 32.26 USD with a low forecast of 29.29 USD and a high forecast of 38.85 USD.

Lowest
Price Target
29.29 USD
1% Downside
Average
Price Target
32.26 USD
9% Upside
Highest
Price Target
38.85 USD
32% Upside
Arcutis Biotherapeutics Inc Competitors:
Price Targets
GLPG
Galapagos NV
9% Upside
ALCLS
Cellectis SA
45% Upside
ELDN
Eledon Pharmaceuticals Inc
380% Upside
068270
Celltrion Inc
19% Upside
688366
Shanghai Haohai Biological Technology Co Ltd
59% Upside
MDGL
Madrigal Pharmaceuticals Inc
0% Upside
ENTA
Enanta Pharmaceuticals Inc
37% Upside
2480
Beijing Luzhu Biotechnology Co Ltd
37% Upside

Revenue
Forecast

Revenue Estimate
Arcutis Biotherapeutics Inc

The compound annual growth rate of Arcutis Biotherapeutics Inc's revenue for the next 3 years is 47%.

N/A
Past Growth
47%
Estimated Growth
Estimates Accuracy
4%
Average Beat

Operating Income
Forecast

Operating Income Estimate
Arcutis Biotherapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-5%
Average Miss

Net Income
Forecast

Net Income Estimate
Arcutis Biotherapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-59%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is ARQT's stock price target?
Price Target
32.26 USD

According to Wall Street analysts, the average 1-year price target for ARQT is 32.26 USD with a low forecast of 29.29 USD and a high forecast of 38.85 USD.

What is Arcutis Biotherapeutics Inc's Revenue forecast?
Projected CAGR
47%

The compound annual growth rate of Arcutis Biotherapeutics Inc's revenue for the next 3 years is 47%.

Back to Top